Cellular Senescence, Cardiovascular Risk, and CKD: A Review of Established and Hypothetical Interconnections

American Journal of Kidney Diseases

Volumn 51, Issue 1, 2008, Pages 131-144

  Tsirpanlis, George ^a  

^a KAT HOSPITAL   (Greece)

Author keywords

atherosclerosis; diabetes; endothelial progenitor cell; hypertension; inflammation; oxidative stress; p53; renal failure; telomerase; Telomeres

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; EBSELEN; NITRIC OXIDE; PRAVASTATIN; RALOXIFENE; TELOMERASE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL AGING; CELL CYCLE; CELL DIVISION; CELL FUNCTION; CELL POPULATION; CELL STRESS; CELL STRUCTURE; CELL TYPE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; HYPOTHESIS; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; REVIEW; STEM CELL; TELOMERE;

CARDIOVASCULAR DISEASES; CELL AGING; HUMANS; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; RISK FACTORS;

EID: 37349080616     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.07.035     Document Type: Review

References (151)

1. Lakatta E.G., and Levy D. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises. Part I: Aging arteries: A "set up" for vascular disease. Circulation 107 (2003) 139-146
2. Braunwald E., and Zipes D.P. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. (ed 7) (2005), Saunders, Philadelphia, PA
3. Marin J. Age-related changes in vascular responses: A review. Mech Ageing Dev 79 (1995) 71-114
4. Schneiderman J., Sawdey M.S., Keeton M.R., et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 89 (1992) 6998-7002
5. Wilkerson W.R., and Sane D.C. Aging and thrombosis. Semin Thromb Hemost 28 (2002) 555-568
6. Lakatta E.G. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises. Part III: Cellular and molecular clues to heart and arterial aging. Circulation 107 (2003) 490-497
7. Minamino T., and Komuro I. Vascular cell senescence: Contribution to atherosclerosis. Circ Res 100 (2007) 15-26
8. Locatelli F., Bommer J., London G.M., et al. Cardiovascular disease determinants in chronic renal failure: Clinical approach and treatment. Nephrol Dial Transplant 16 (2001) 459-468
9. Tsirpanlis G. The pattern of inflammation and a potential new clinical meaning and usefulness of C-reactive protein in end-stage renal failure patients. Kidney Blood Press Res 28 (2005) 55-61
10. Levey A.S., Beto J.A., Coronado B.E., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?. Am J Kidney Dis 32 (1998) 853-906
11. Foley R.N., Parfrey P.S., and Sarnak M. Epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 32 suppl 3 (1998) S112-S119
12. Parfrey P.S., and Foley R.N. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10 (1999) 1606-1615
13. Fuster J.J., and Andres V. Telomere biology and cardiovascular disease. Circ Res 99 (2006) 1167-1180
14. Chen J., and Goligorsky M.S. Premature senescence of endothelial cells: Methusaleh's dilemma. Am J Physiol Heart Circ Physiol 290 (2006) 1729-1739
15. Ben-Porath I., and Weinberg R.A. When cells get stressed: An integrative view of cellular senescence. J Clin Invest 113 (2004) 8-13
16. Wright W.E., and Shay J.W. Historical claims and current interpretations of replicative aging. Nat Biotechnol 20 (2002) 682-688
17. Sherr C.J., and DePinho R.A. Cellular senescence: Mitotic clock or culture shock?. Cell 102 (2000) 407-410
18. Campisi J. Cancer, aging and cellular senescence. In Vivo 14 (2000) 183-188
19. Sitte N., Merker K., Von Zglinicki T., Grune T., and Davies K.J. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts. I. Effects of proliferative senescence. FASEB J 14 (2000) 2495-2502
20. Narita M., Nunez S., Heard E., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113 (2003) 703-716
21. Serrano M., and Blasco M.A. Putting the stress on senescence. Curr Opin Cell Biol 13 (2001) 748-753
22. Ben-Porath I., and Weinberg R.A. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 37 (2005) 961-976
23. Campisi J. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120 (2005) 513-522
24. Parrinello S., Coppe J.-P., Krtolica A., and Campisi J. Stromal-epithelial interactions in aging and cancer: Senescent fibroblasts alter epithelial cell differentiation. Cell Sci 118 (2005) 485-496
25. Zhang H., Pan K.-H., and Cohen S.N. Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proc Natl Acad Sci U S A 100 (2003) 3251-3256
26. Krtolica A., and Campisi J. Cancer and aging: A model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol 34 (2002) 1401-1414
27. Gire Roux P., Wynford-Thomas D., Brondello J.M., and Dulic V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J 23 (2004) 2554-2563
28. Kaneko T., Tahara S., Taguchi T., and Kondo H. Accumulation of oxidative DNA damage, 8-oxo-2′-deoxyguanoside, and change of repair systems during in vitro cellular aging of cultured human skin fibroblasts. Mutat Res 487 (2001) 19-30
29. Chen Q., and Ames B.N. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci U S A 91 (1994) 4130-4134
30. Robles S.J., and Adami G.R. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 16 (1998) 1113-1123
31. Lloyd A.C. Limits to lifespan. Nat Cell Biol 4 (2002) E25-E27
32. Vousden K.H., and Lane D.P. P53 in health and disease. Nat Rev Mol Cell Biol 8 (2007) 275-283
33. Shay J.W., Pereira-Smith O.M., and Wright W.E. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 196 (1991) 33-39
34. Satyanarayana A., Wiemann S.U., Buer J., et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J 22 (2003) 4003-4013
35. Schmitt C.A., Fridman J.S., Yang M., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109 (2002) 335-346
36. Dimri G.P., Lee X., Basile G., et al. A novel biomarker identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92 (1995) 9363-9367
37. Kuju K.S., and Lehman J.M. Increased p53 protein associated with aging in human diploid fibroblasts. Exp Cell Res 217 (1995) 336-345
38. Dirac A.M., and Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem 278 (2003) 11731-11734
39. Castro M.E., del Valle Guijarro M., Moneo V., and Carnero A. Cellular senescence induced by p-53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. J Cell Biochem 92 (2004) 514-524
40. Favetta L.A., Robert C., King W.A., and Betts D.H. Expression profiles of p53 and p66shc during oxidative stress-induced senescence in fetal bovine fibroblasts. Exp Cell Res 299 (2004) 36-48
41. 2 response of normal human fibroblasts. Biochem J 347 (2000) 543-551
42. 2: Senescence-like growth arrest or apoptosis?. Cell Growth Differ 8 (1997) 589-598
43. Rincheval V., Renaud F., Lemaire C., et al. Bcl-2 can promote p-53 dependent senescence versus apoptosis without affecting the G1/S transition. Biochem Biophys Res Commun 298 (2002) 282-288
44. Rebbaa A., Zheng X., Chou P.M., and Mirkin B.L. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 22 (2003) 2805-2811
45. Zhang J., Patel J.M., and Block E.R. Enhanced apoptosis in prolonged cultures of senescent porcine pulmonary artery endothelial cells. Mech Ageing Dev 123 (2002) 613-625
46. Blackburn E.H. Telomeres and telomerase: Their mechanism of action and the effects of altering their functions. FEBS Lett 579 (2005) 859-862
47. Cech T.R. Beginning to understand the end of the chromosome. Cell 116 (2004) 273-279
48. Blackburn E.H. Switching and signaling at the telomere. Cell 106 (2001) 661-673
49. Blasco M.A. Telomeres and human disease: Ageing, cancer and beyond. Nat Rev Genet 6 (2005) 611-622
50. McElligott R., and Wellinger R.J. The terminal DNA structure of mammalian chromosomes. EMBO J 16 (1997) 3705-3714
51. Wellinger R.J., and Sen D. The DNA structures at the ends of eukaryotic chromosomes. Eur J Cancer 33 (1997) 735-749
52. Wright W.E., Tesmer V.M., Huffman K.E., Levene S.D., and Shay J.W. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev 11 (1997) 2801-2809
53. Griffith J.D., Comeau L., Rosenfield S., et al. Mammalian telomeres end in a large duplex loop. Cell 97 (1999) 503-514
54. Harley C.B., Futcher A.B., and Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 345 (1990) 458-460
55. Karlseder J., Smogorzewska A., and de Lange T. Senescence induced by altered telomere state, not telomere loss. Science 295 (2002) 2446-2449
56. Li C.-Z., Eller M.S., Firoozabadi R., and Gilchrest B.A. Evidence that exposure of the telomere 3′ overhang sequence induces senescence. Proc Natl Acad Sci U S A 100 (2003) 527-531
57. Bodnar A.G., Quellete M., Frolkis M., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 279 (1998) 349-352
58. Vaziri H., and Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 8 (1998) 279-282
59. Zhu J., Wang H., Bishop J.M., and Blackburn E.H. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci U S A 96 (1999) 3723-3728
60. Masutomi K., Yu E.Y., Khurts S., et al. Telomerase maintains telomere structure in normal human cells. Cell 114 (2003) 241-253
61. Geserick C., and Blasco M.A. Novel roles for telomerase in aging. Mech Aging Dev 127 (2006) 579-583
62. Minamino T., Miyauchi H., Yoshida T., Ishida Y., Yoshida H., and Komuro I. Endothelial cell senescence in human atherosclerosis: Role of telomere in endothelial dysfunction. Circulation 105 (2002) 1541-1544
63. Vasile E., Tomita Y., Brown L.F., Kocher O., and Dvorak H.F. Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: Evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J 15 (2001) 458-466
64. Fenton M., Barker S., Kurz D.J., and Erusalimsky J.D. Cellular senescence after single and repeated balloon catheter denudations of rabbit carotid arteries. Arterioscler Thromb Vasc Biol 21 (2001) 220-226
65. Liao S., Curci J.A., Kelley B.J., Sicard G.A., and Thompson R.W. Accelerated replicative senescence of medial smooth muscle cells derived from abdominal aortic aneurysms compared to the adjacent inferior mesenteric artery. J Surg Res 92 (2000) 85-95
66. Brandes R.P., Fleming I., and Busse R. Endothelial aging. Cardiovasc Res 66 (2005) 286-294
67. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 27 (2007) 266-274
68. Haendeler J. Nitric oxide and endothelial cell aging. Eur J Clin Pharmacol 62 (2006) 137-140
69. Dimmeler S., and Zeiher A.M. Nitric oxide-An endothelial cell survival factor. Cell Death Differ 6 (1999) 964-968
70. Hoffman J., Haendeler J., Aicher A., et al. Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: Important role of nitric oxide. Circ Res 89 (2001) 709-715
71. Matsushita H., Chang E., Glassford A.J., Cooke J.P., Chiu C.-P., and Tsao P.S. eNOS activity is reduced in senescent human endothelial cells. Preservation by hTERT immortalization. Circ Res 89 (2001) 793-798
72. Vasa M., Breitschopf K., Zeiher A.M., and Dimmeler S. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ Res 87 (2000) 540-542
73. Hayashi T., Matsui-Hirai H., Miyazaki-Akita A., et al. Endothelial cellular senescence is inhibited by nitric oxide: Implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci USA 103 (2006) 17018-17023
74. Kurz D.J., Decary S., Hong Y., Trivier E., Akhmedov A., and Erusalimsky J.D. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci 117 (2004) 2417-2426
75. Deshpande S.S., Qi B., Park Y.C., and Irani K. Constitutive activation of rac1 results in mitochondrial oxidative stress and induces premature endothelial cell senescence. Arterioscler Thromb Vasc Biol 23 (2003) e1-e6
76. van der Loo B., Labugger R., Skepper J.N., et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 192 (2000) 1731-1744
77. Scalera F., Borlak J., Beckmann B., et al. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl l-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol 24 (2004) 1816-1822
78. Shelton D.N., Chang E., Whittier P.S., Choi D., and Funk W.D. Microarray analysis of replicative senescence. Curr Biol 9 (1999) 939-945
79. Effros R.B. Telomerase induction in T cells: A cure for aging and disease?. Exp Gerontol 42 (2007) 416-420
80. + T-cell replicative senescence in human aging. Immunol Rev 205 (2005) 147-157
81. Maier J.A., Statuto M., and Ragnotti G. Senescence stimulates U937-endothelial cell interactions. Exp Cell Res 208 (1993) 270-274
82. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362 (1993) 801-809
83. Henson P.M. Dampening inflammation. Nat Immunol 6 (2005) 1179-1181
84. Serhan C.N., and Savill J. Resolution of inflammation: The beginning programs the end. Nat Immunol 6 (2005) 1191-1197
85. Liu J., Thewke D.P., Ru Su Y., Linton M.R.F., Fazio S., and Sinensky M.S. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol 25 (2005) 174-179
86. Guevara N.V., Kim H.-S., Antonova E.I., and Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med 5 (1999) 335-339
87. van Vlijmen B.J.M., Gerritsen G., Franken A.L., et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE 3-Leiden transgenic mice. Circ Res 88 (2001) 780-786
88. Merched A.J., Williams E., and Chan L. Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler Thromb Vasc Biol 23 (2003) 1608-1614
89. Ogawa D., Nomiyama T., Nakamachi T., et al. Activation of peroxisome proliferator-activated receptor γ suppresses telomerase activity in vascular smooth muscle cells. Circ Res 98 (2006) e50-e59
90. Poch E., Carbonell P., Franco S., Díez-Juan A., Blasco M.A., and Andrés V. Short telomeres protect from diet-induced atherosclerosis in apolipoprotein E-null mice. FASEB J 18 (2004) 418-420
91. Matthews C., Gorenne I., Scott S., et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis. Effects of telomerase and oxidative stress. Circ Res 99 (2006) 156-164
92. - mice after adenovirus-mediated transfer of p53. Circulation 105 (2002) 2064-2070
93. Clarke M., and Bennett M. The emerging role of vascular smooth muscle cell apoptosis in atherosclerosis and plaque stability. Am J Nephrol 26 (2006) 531-535
94. Koenig W., and Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 27 (2007) 15-26
95. Nyunoya T., Monick M.M., Klingelhutz A., Yarovinsky T.O., Cagley J.R., and Hunninghake G.W. Cigarette smoke induces cellular senescence. Am J Respir Cell Mol Biol 35 (2006) 681-688
96. Chen J., Brodsky S.V., Goligorsky D.M., et al. Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res 90 (2002) 1290-1298
97. Kunieda T., Minamino T., Nishi J., et al. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation 114 (2006) 953-960
98. Kunieda T., Minamino T., Katsuno T., et al. Cellular senescence impairs circadian expression of clock genes in vitro and in vivo. Circ Res 98 (2006) 532-539
99. Misiti S., Nanni S., Fontemaggi G., et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol 20 (2000) 3764-3771
100. Perez-Rivero G., Ruiz-Torres M.P., Rivas-Elena J.V., et al. Mice deficient in telomerase activity develop hypertension because of an excess of endothelin production. Circulation 114 (2006) 309-317
101. Gardner J.P., Li S., Srinivasan S.R., et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation 111 (2005) 2171-2177
102. Adaikalakoteswari A., Balasubramanyam M., Ravikumar R., Deepa R., and Mohan V. Association of telomere shortening with impaired glucose tolerance and diabetic macroangiopathy. Atherosclerosis 195 (2007) 83-89
103. Adaikalakoteswari A., Balasubramanyam M., and Mohan V. Telomere shortening occurs in Asian Indian type 2 diabetic patients. Diabet Med 22 (2005) 1151-1156
104. Sampson M.J., Winterbone M.S., Hughes J.C., Dozio N., and Hughes D.A. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care 29 (2006) 283-289
105. Aviv A., Valdes A., Gardner J.P., Swaminathan R., Kimura M., and Spector T.D. Menopause modifies the association of leukocyte telomere length with insulin resistance and inflammation. J Clin Endocrinol Metab 91 (2006) 635-640
106. Jeanclos E., Schork N.J., Kyvik K.O., Kimura M., Skurnick J.H., and Aviv A. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension 36 (2000) 195-200
107. Valdes A.M., Andrew T., Gardner P., et al. Obesity, cigarette smoking, and telomere length in women. Lancet 366 (2005) 662-664
108. Demissie S., Levy D., Benjamin E.J., et al. Insulin resistance, oxidative stress, hypertension, and leukocyte length in men from the Framingham Heart Study. Aging Cell 5 (2006) 325-330
109. Epel E.S., Blackburn E.H., Lin J., et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A 101 (2004) 17312-17315
110. Epel E.S., Lin J., Wilhelm F.H., et al. Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology 31 (2006) 277-287
111. Urbich C., and Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 95 (2004) 343-353
112. Heiss C., Keymel S., Niesler U., Ziemann J., Kelm M., and Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol 45 (2005) 1441-1448
113. Imanishi T., Hano T., and Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 23 (2005) 97-104
114. Imanishi T., Hano T., Sawamura T., and Nishio I. Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clin Exp Pharmacol Physiol 31 (2004) 407-410
115. Verma S., Kuliszewski M.A., Li S.-H., et al. C-Reactive protein attenuates endothelial progenitor cell survival, differentiation, and function. Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109 (2004) 2058-2067
116. Fujii H., Li S.H., Szmitko P.E., Fedak P., and Verma S. C-Reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol 26 (2006) 2476-2482
117. Imanishi T., Moriwaki C., Hano T., and Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 23 (2005) 1831-1837
118. Aviv A., Valdes A.M., and Spector T.D. Human telomere biology: Pitfalls of moving from the laboratory to epidemiology. Int J Epidemiol 35 (2006) 1424-1429
119. Nawrot T.S., Staessen J.A., Gardner J.P., and Aviv A. Telomere length and possible link to X chromosome. Lancet 363 (2004) 507-510
120. Andrew T., Aviv A., Falchi M., et al. Mapping genetic loci that determine leukocyte telomere length in a large sample of unselected, female sibling pairs. Am J Hum Genet 78 (2006) 480-486
121. Vasa-Nicotera M., Brouilette S., Mangino M., et al. Mapping of a major locus that determines telomere length in humans. Am J Hum Genet 76 (2005) 147-151
122. Blasco M.A. The epigenetic regulation of mammalian telomeres. Nat Rev Genet 8 (2007) 299-309
123. Atkinson S.P., and Keith W.N. Epigenetic control of cellular senescence in disease: Opportunities for therapeutic intervention. Expert Rev Mol Med 9 (2007) 1-26
124. Cherkas L.F., Aviv A., Valdes A.M., et al. The effects of social status on biological ageing as measured by white cell telomere length. Aging Cell 5 (2006) 361-367
125. Krabbe K.S., Pedersen M., and Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 39 (2004) 687-699
126. Hansson G.K., Robertson A.-K., and Soderberg-Naucler C. Inflammation and atherosclerosis. Ann Rev Pathol Mech Dis 1 (2006) 297-329
127. Tsirpanlis G. Inflammation in atherosclerosis and other conditions: A response to danger. Kidney Blood Press Res 28 (2005) 211-217
128. Stocker R., and Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 84 (2004) 1381-1478
129. Samani N.J., Boultby R., Butler R., Thompson J.R., and Goodall A.H. Telomere shortening in atherosclerosis. Lancet 358 (2001) 472-473
130. Cawthon R.M., Smith K.R., O'Brien E., Sivatchenko A., and Kerber R.A. Association between telomere length blood and mortality in people aged 60 years or older. Lancet 361 (2003) 393-395
131. Brouilette S., Singh R.K., Thompson J.R., Goodall A.H., and Samani N.J. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 23 (2003) 842-846
132. Obana N., Takagi S., Kinouchi Y., et al. Telomere shortening of peripheral blood mononuclear cells in coronary disease patients with metabolic disorders. Intern Med 42 (2003) 150-153
133. Benetos A., Gardner J.P., Zureik M., et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 43 (2004) 182-185
134. Collerton J., Martin-Ruiz C., Kenny A., et al. Telomere length is associated with left ventricular function in the oldest old: The Newcastle 85+ study. Eur Heart J 28 (2007) 172-176
135. Bischoff C., Petersen H.C., Graakjaer J., et al. No association between telomere length and survival among the elderly and oldest old. Epidemiology 17 (2006) 190-194
136. Fitzpatrick A.L., Kronmal R.A., Gardner J.P., et al. Leukocyte telomere length and cardiovascular disease in the Cardiovascular Health Study. Am J Epidemiol 165 (2007) 14-21
137. Brouilette S.W., Moore J.S., McMahon A.D., et al. Telomere length, risk of coronary disease, and statin treatment in the West of Scotland Primary Prevention Study: A nested case-control study. Lancet 369 (2007) 107-114
138. Assmus B., Urbich C., Aicher A., et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 92 (2003) 1049-1055
139. Spyridopoulos I., and Dimmeler S. Can telomere length predict cardiovascular risk?. Lancet 369 (2007) 81-82
140. Spyridopoulos I., Haendeler J., Urbich C., et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 110 (2004) 3136-3142
141. Haendeler J., Hoffmann J., Diehl J.F., et al. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ Res 94 (2004) 768-775
142. Brodsky S.V., Gealekman O., Chen J., et al. Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ Res 94 (2004) 377-384
143. Bode-Boger S.M., Martens-Lobenhoffer J., Tager M., Schroder H., and Scalera F. Aspirin reduces endothelial cell senescence. Biochem Biophys Res Commun 334 (2005) 1226-1232
144. Scalera F., Martens-Lobenhoffer J., Tager M., Bukowska A., Lendeckel U., and Bode-Boger S.M. Effect of l-arginine on asymmetric dimethylarginine (ADMA) or homocysteine-accelerated endothelial cell aging. Biochem Biophys Res Commun 245 (2006) 1075-1082
145. Doshida M., Ohmichi M., Tsutsumi S., et al. Raloxifene increases proliferation and upregulates telomerase activity in human umbilical vein endothelial cells. J Biol Chem 281 (2006) 24270-24278
146. Ramirez R., Carracedo J., Soriano S., et al. Stress-induced premature senescence in mononuclear cells from patients on long-term hemodialysis. Am J Kidney Dis 45 (2005) 353-359
147. Jimenez R., Carracedo J., Santamaria R., et al. Replicative senescence in patients with chronic kidney failure. Kidney Int Suppl 99 (2005) S11-S15
148. Boxall M.C., Goodship T., Brown A.L., Ward M.C., and von Zglinicki T. Telomere shortening and haemodialysis. Blood Purif 24 (2006) 185-189
149. Tsirpanlis G., Chatzipanagiotou S., Boufidou F., et al. Telomerase activity is decreased in peripheral blood mononuclear cells of hemodialysis patients. Am J Nephrol 26 (2006) 91-96
150. Tsirpanlis G., Chatzipanagiotou S., Boufidou F., et al. Serum oxidized low-density lipoprotein is inversely correlated to telomerase activity in peripheral blood mononuclear cells of haemodialysis patients. Nephrology (Carlton) 11 (2006) 506-509
151. Uhlig K., MacLeod A., Craig J., et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 70 (2006) 2058-2065